Mascarenhas, J., Scandura, J., Gupta, V., Shimoda, K., McCloskey, J., Chaer, F. E., Bose, P., Rampal, R., Srisuwananukorn, A., Devos, T., Mesa, R., Passamonti, P. F., Tantravahi, S., Ross, D., Rein, L., Kiladjian, J., Teshima, T., Yamauchi, T., Asada, N., Halpern, A., Haque, T., Paubelle, E., Fukuhara, N., Vachhani, P., Ichii, M., Hoffman, R., Rotta, M., Keng, M., Wickenhauser, S., Ansaldo, K., Seki, M., Lee, J., Loksa, V., Li, Z., Foulks, J., Kabir, S., Shah, J., Harrison, C. (2025). Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis. Blood. https://doi.org/10.1182/blood-2025-482